ArticleBritish journal of cancer2022
Immune biomarkers and response to checkpoint inhibition of BRAF
Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies.Journal of thoracic disease · 2026Review
- Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell communication and signaling : CCS · 2025Review
- Article
- Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer withAmerican journal of cancer research · 2025Article
- Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) ofLung Cancer (Auckland, N.Z.) · 2025Article
- Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics.Lung Cancer (Auckland, N.Z.) · 2025Review
- Exploring immunotherapy efficacy in non-small cell lung cancer patients withTranslational lung cancer research · 2024Article
- Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The evolving treatment landscape for BRAF-mutated non-small cell lung cancer.Translational lung cancer research · 2024Article
- Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.Clinical and experimental medicine · 2024Review
- The rapidly changing field of predictive biomarkers of non-small cell lung cancer.Pathology oncology research : POR · 2024Review
- Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer.OncoTargets and therapy · 2024Review
- Outcomes of non-small cell lung cancer patients with non-V600EFrontiers in oncology · 2024Article
- Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.International journal of molecular sciences · 2023Article
- At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.Nature reviews. Clinical oncology · 2023Review
- Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboringTranslational lung cancer research · 2023Article
- Non-small-cell lung cancer: how to manageDrugs in context · 2023Review
- Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients HarboringCancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundWhile 2-4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours.
methodsClinical and genomic data were collected from 5945 patients with lung cancers whose tumours underwent next-generation sequencing between 2015 and 2018. Patients were followed through 2020.
resultsIn total, 127 patients with metastatic BRAF-altered lung cancers were identified: 29 tumours had Class I mutations, 59 had Class II/III alterations, and 39 had variants of unknown significance (VUS). Tumour mutation burden was higher in Class II/III than Class I-altered tumours (8.8 mutations/Mb versus 4.9, P < 0.001), but this difference was diminished when stratified by smoking status. The overall response rate to immune checkpoint inhibitors (ICI) was 9% in Class I-altered tumours and 26% in Class II/III (P = 0.25), with median time on treatment of 1.9 months in both groups. Among patients with Class I-III-altered tumours, 36-month HR for death in those who ever versus never received ICI was 1.82 (1.17-6.11). Nine patients were on ICI for >2 years (two with Class I mutations, two with Class II/III alterations, and five with VUS).
conclusionsA subset of patients with BRAF-altered lung cancers achieved durable disease control on ICI. However, collectively no significant clinical benefit was seen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.